Patent · US Active

Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC7 ion channels

US8455469B2 · kind B2 · utility

0Cited by

0References

10Claims

0Family size

Assignee

Sanofi · FR

Inventors

Susanne Miehe · Frankfurt am Main, DE
Heinz-Werner Kleemann · Bischofsheim, DE
Carsten Struebing · Frankfurt, DE

Key dates

Filing date	Oct 14, 2008
Grant date	Jun 4, 2013
Priority date	—
Expiry date	Jul 17, 2029

Classification

Technology area (CPC G)Physics
CPC primaryG01N2500/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

TRPC ion channels are non-selective channels widely expressed in human tissues. These channels are involved in numerous physiological functions and are putative targets for the development of novel medicines. There is a need to gain a better understanding of TRPC ion channels in cells and beyond. The present invention provides a pharmacological tool compound that allows to study TRPC ion channels due to its discriminating inhibition of TRPC subfamilies. In the present invention, norgestimate is shown to selectively inhibit TRPC3, TRPC6 and TRPC7.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.